Media stories about Enzo Biochem (NYSE:ENZ) have trended positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.33 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.2673214642354 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- What Will Happen to Enzo Biochem, Inc. (ENZ) Next? The Stock Just Reaches 1 Year Low – NMSU Hеrаld (nmsuherald.com)
- Head-To-Head Comparison: Enzo Biochem (ENZ) versus Its Competitors (americanbankingnews.com)
- Edited Transcript of ENZ earnings conference call or presentation 13-Mar-18 12:30pm GMT (finance.yahoo.com)
- Enzo Biochem, Inc. (ENZ) price is down -33.57% off its 200-SMA – The Stocks News (press release) (thestocksnews.com)
ENZ stock traded down $0.07 during midday trading on Wednesday, hitting $6.17. The stock had a trading volume of 220,359 shares, compared to its average volume of 183,327. Enzo Biochem has a 52 week low of $6.11 and a 52 week high of $12.04. The firm has a market capitalization of $302.67, a price-to-earnings ratio of -205.67 and a beta of 0.84.
Separately, ValuEngine lowered Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st.
In other Enzo Biochem news, CFO Barry W. Weiner sold 11,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total transaction of $85,250.00. Following the transaction, the chief financial officer now owns 1,313,111 shares of the company’s stock, valued at approximately $10,176,610.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Elazar Rabbani sold 14,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the transaction, the chief executive officer now directly owns 1,867,202 shares in the company, valued at approximately $14,470,815.50. The disclosure for this sale can be found here. 8.90% of the stock is currently owned by company insiders.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.
